AR125296A1 - Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 - Google Patents

Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1

Info

Publication number
AR125296A1
AR125296A1 ARP220100836A ARP220100836A AR125296A1 AR 125296 A1 AR125296 A1 AR 125296A1 AR P220100836 A ARP220100836 A AR P220100836A AR P220100836 A ARP220100836 A AR P220100836A AR 125296 A1 AR125296 A1 AR 125296A1
Authority
AR
Argentina
Prior art keywords
antigen
methods
binding fragment
subcutaneous administration
cancer
Prior art date
Application number
ARP220100836A
Other languages
English (en)
Spanish (es)
Inventor
Miranda Silva Carolina De
Elliot Keith Chartash
Ferdous Gheyas
Lokesh Jain
Mallika Lala
Venkata Naga Ratna Pavan Kumar Vaddady
Yogita Krishnamachari
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of AR125296A1 publication Critical patent/AR125296A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP220100836A 2021-04-08 2022-04-04 Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 AR125296A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163172299P 2021-04-08 2021-04-08

Publications (1)

Publication Number Publication Date
AR125296A1 true AR125296A1 (es) 2023-07-05

Family

ID=83546458

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100836A AR125296A1 (es) 2021-04-08 2022-04-04 Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1

Country Status (21)

Country Link
US (1) US20250074983A1 (enExample)
EP (1) EP4320163A4 (enExample)
JP (1) JP2024513247A (enExample)
KR (1) KR20230170029A (enExample)
CN (1) CN117279952A (enExample)
AR (1) AR125296A1 (enExample)
AU (1) AU2022254960A1 (enExample)
BR (1) BR112023020867A2 (enExample)
CA (1) CA3214617A1 (enExample)
CL (1) CL2023002976A1 (enExample)
CO (1) CO2023013273A2 (enExample)
CR (1) CR20230473A (enExample)
DO (1) DOP2023000216A (enExample)
EC (1) ECSP23076276A (enExample)
GE (1) GEAP202416385A (enExample)
IL (1) IL307430A (enExample)
JO (1) JOP20230243A1 (enExample)
MX (1) MX2023011857A (enExample)
PE (1) PE20240051A1 (enExample)
TW (1) TW202305009A (enExample)
WO (1) WO2022216580A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102650991B1 (ko) 2019-03-25 2024-03-27 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
WO2025140467A1 (zh) * 2023-12-29 2025-07-03 上海复宏汉霖生物技术股份有限公司 稳定的高浓度抗pd-1抗体药物制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US20160084839A1 (en) 2013-04-02 2016-03-24 Marisa Dolled-Filhart Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018223182A1 (en) * 2017-06-05 2018-12-13 The Council Of The Queensland Institute Of Medical Research A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefor.
JP2021513540A (ja) * 2018-02-13 2021-05-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
EP3876978A4 (en) * 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
KR102650991B1 (ko) * 2019-03-25 2024-03-27 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물

Also Published As

Publication number Publication date
TW202305009A (zh) 2023-02-01
KR20230170029A (ko) 2023-12-18
JP2024513247A (ja) 2024-03-22
WO2022216580A1 (en) 2022-10-13
ECSP23076276A (es) 2023-11-30
CL2023002976A1 (es) 2024-06-28
JOP20230243A1 (ar) 2023-10-08
CO2023013273A2 (es) 2023-10-30
DOP2023000216A (es) 2023-11-30
AU2022254960A9 (en) 2023-11-30
AU2022254960A1 (en) 2023-11-23
EP4320163A4 (en) 2025-03-05
CR20230473A (es) 2023-11-30
MX2023011857A (es) 2023-10-19
CA3214617A1 (en) 2022-10-13
IL307430A (en) 2023-12-01
GEAP202416385A (en) 2024-02-26
US20250074983A1 (en) 2025-03-06
BR112023020867A2 (pt) 2023-12-12
PE20240051A1 (es) 2024-01-09
EP4320163A1 (en) 2024-02-14
CN117279952A (zh) 2023-12-22

Similar Documents

Publication Publication Date Title
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
Rodriguez-Ruiz et al. Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
MX2022001065A (es) Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
BR112023016320A2 (pt) Composição terapêutica e método de combinação de imunoterapia multiplex com vacina contra câncer para tratamento de câncer
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
CL2025003511A1 (es) Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1.
CL2024003729A1 (es) Terapia combinada de agente activo anti-pd-1, agente activo anti-tim-3 y agente activo anti-lag-3 para tratar cáncer.
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
MX2024006799A (es) Metodos para el tratamiento de cáncer con prame positivo.
MX2022003610A (es) Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
DOP2025000008A (es) Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
BR112022009716A2 (pt) Dosagem de um inibidor de tirosina quinase de bruton
AR130745A1 (es) Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
PE20200889A1 (es) METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)
CR20220040A (es) Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab
AR124527A1 (es) Métodos de tratamiento de tumores
PE20250161A1 (es) Dosis para tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3 en pacientes mayores
AR123364A1 (es) Uso de un anticuerpo anti-pd-1 y un fármaco antineoplásico citotóxico en el tratamiento del cáncer de pulmón no microcítico
AR127946A1 (es) ESTIMULADOR TREG SELECTIVO RUR₂₀ₖD-IL-2 Y COMPOSICIONES RELACIONADAS
AR133823A1 (es) Métodos de tratamiento que utilizan agentes de unión a epcam y cd137 en combinación con antagonistas de unión al eje pd-1